Roberta Mussinelli

Pavia, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Laboratory investigations to rule out AL amyloidosis: practical guidance for the cardiologist

Laboratory investigations to rule out AL amyloidosis: practical guidance for the cardiologist

Journal: Giornale italiano di cardiologia (2006)

Published: July 29, 2026

New Validated Staging System for Light Chain (AL) Amyloidosis With Stage IIIC Defining Ultra-Poor Risk: AL International Staging System.

New Validated Staging System for Light Chain (AL) Amyloidosis With Stage IIIC Defining Ultra-Poor Risk: AL International Staging System.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 07, 2025

Eligibility criteria for clinical trials in AL amyloidosis result in exclusion of nearly half of real-world patients.

Eligibility criteria for clinical trials in AL amyloidosis result in exclusion of nearly half of real-world patients.

Journal: HemaSphere

Published: October 13, 2025

Long-term follow-up with magnetic resonance neurography in a patient with hereditary transthyretin amyloidosis treated with inotersen.

Long-term follow-up with magnetic resonance neurography in a patient with hereditary transthyretin amyloidosis treated with inotersen.

Journal: Journal of the neurological sciences

Published: August 04, 2025

High-Sensitivity Cardiac Troponin I for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy.

High-Sensitivity Cardiac Troponin I for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy.

Journal: Circulation. Heart failure

Published: May 15, 2025

Left ventriculo-arterial coupling in a contemporary cohort of patients with wild-type transthyretin cardiac amyloidosis treated with tafamidis.

Left ventriculo-arterial coupling in a contemporary cohort of patients with wild-type transthyretin cardiac amyloidosis treated with tafamidis.

Journal: Clinical research in cardiology : official journal of the German Cardiac Society

Published: April 12, 2025

Neurohormonal therapies at baseline and follow-up and survival in wild-type transthyretin cardiac amyloidosis.

Neurohormonal therapies at baseline and follow-up and survival in wild-type transthyretin cardiac amyloidosis.

Journal: Journal of cardiovascular medicine (Hagerstown, Md.)

Published: April 02, 2025

Cascade genetic screening in families with hereditary transthyretin amyloidosis: diagnostic and prognostic impact.

Cascade genetic screening in families with hereditary transthyretin amyloidosis: diagnostic and prognostic impact.

Journal: European heart journal

Published: February 26, 2025

Change in prevalence of ATTR variants in Italy: results from a national survey.

Change in prevalence of ATTR variants in Italy: results from a national survey.

Journal: European heart journal. Quality of care & clinical outcomes

Published: February 07, 2025

Predictors of Early Death in Patients With Wild-Type Transthyretin Cardiac Amyloidosis.

Predictors of Early Death in Patients With Wild-Type Transthyretin Cardiac Amyloidosis.

Journal: Journal of the American Heart Association

Published: December 24, 2024

Diagnostic Performance of the New Free Light Chain Ratio in Systemic Amyloidosis.

Diagnostic Performance of the New Free Light Chain Ratio in Systemic Amyloidosis.

Journal: JACC. CardioOncology

Published: December 17, 2024

Daratumumab-based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case-control study.

Daratumumab-based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case-control study.

Journal: HemaSphere

Published: November 17, 2024

Showing 1-12 of 44

Last Updated: 09/26/2026